South Korea’s two largest pharmaceutical companies have agreed to cooperate on developing treatments for rare diseases.GC Pharma, formerly known as Green Cross Corporation, and Yuhan Corporation announced on June 19 that the two companies signed a memorandum of understanding (MOU) on joint research
Orphan drugs, which refer to drugs developed to treat rare diseases, are emerging as a new battlefield for global pharmaceutical companies. They have been neglected by the industry because the number of rare disease patients is small and it is hard to carry out clinical trials. However, orphan drugs
Green Cross announced on July 5 that it has signed a contract for “business alliance” with Korea-based biopharmaceutical company ISU Abxis to cooperate for the local distribution of Abcertin, a treatment for Gaucher's disease.Under the contract, Green Cross will be responsible for the domestic distr
In March of this year Dong-A Pharmaceutical Company separated its research center into two parts: Dong-A Socio Holdings Research Center and Dong-A ST Research Center. It also established a new research laboratory for revolutionary medicine in the research center of a shareholding company, all in ord